

Electronically filed on April 20, 2009

Customer No.: 20462
Confirmation No. 7087

Attorney Docket No. PU60756

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lee, et al.	Date:	April 20, 2009
Serial No.:	10/589,995	Group Art Unit No.:	1625
Filed:	August 18, 2006	Examiner:	Patricia L. Morris
For:	PYRIDONE		

Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(c) and
Statement under 37 C.F.R. §1.97(e)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except U.S. patent documents, and those documents already part of the filewrapper. This information disclosure statement is being filed with a Statement as specified in 37 C.F.R. §1.97(e) and without any fee in accordance with the provisions of 37 C.F.R. §1.97(c)(1), and before the mailing a Final Action under 37 CFR §1.113, or a Notice of Allowance under 37 CFR §1.311 as specified in 37 C.F.R. §1.97(c).

Statement Under 37 C.F.R. §1.97(c) The undersigned hereby state:

that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. §1.97(c)(1).

Respectfully submitted,



Reid S. Willis
Attorney for Applicants
Registration No. 39,429

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7481
Facsimile (610) 270-5090